Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

A psilocybin mushroom, also known as a magic mushroom, offers infinite medical and scientific potential…from cognitive flexibility to potentially addressing clinical depression and eating disorders. There’s a lot we still don’t kn...
Dave Jackson | September 18, 2020 |

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. Oncology-focused...
Streetwise Reports | March 3, 2020 |

Two Approvals Underscore Biotech's Pipeline Quality

The green lights and their implications are discussed in an H.C. Wainwright & Co. report. In a Jan. 22 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the European Commission approved the regimen consisting of Genmab A/S' (GMAB:NASD...
Streetwise Reports | January 30, 2020 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

A steady diet of plastic

People eating fish are advised to watch carefully for bones, but how about tiny pieces of plastic? For years it has been known that plastic breaks down into microscopic particles that are consumed by shellfish, fish and mammals higher up the food chain, presentin...
Richard (Rick) Mills | August 21, 2019 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

How Much Crude Oil Do You Unknowingly Eat?

You may think (or hope) that in your daily life you don't need to worry about unknowingly eating or otherwise ingesting crude oil or any of its many, many petrochemical byproducts. But you would be wrong. And not just a little wrong--very, very wrong. Petroleum-based substance...
Haley Zaremba | December 5, 2019 |

Your One-stop-shop for All Things Plant-based is This Company

(Click image to play video) It’s no secret that the alternative meat and plant-based sector has gone through tremendous growth over the last several years as people shift away from animal-based products. Similarly, companies are also cap...
Jocelyn Aspa | May 4, 2021 |

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. In a March 18 research note, H.C. Wainwright & Co. analyst Andrew Fein purported that Constellation Pharmaceuticals Inc.'s (CNST:NASDAQ) "strong and balanced pi...
Streetwise Reports | March 25, 2019 |

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. In an April 29 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Forty Seven Inc. (FTSV...
Streetwise Reports | May 2, 2019 |
1 2 3 4 5